


Friday Satellite Symposia

Preceding the 64th ASH Annual Meeting and Exposition

HOW WE DO IT: Application of State-of-the-Art MF and PV Care Today...

With An Eye Toward How
New Evidence and
Combinations Will be
Leveraged Tomorrow



IN-PERSON + LIVE STREAMING SATELLITE SYMPOSIUM

FRIDAY, DECEMBER 9, 2022

11:00 AM - 1:30 PM CT

PROGRAM CHAIR

Andrew Kuykendall, MD

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #GoToPER.

Dear Colleague:

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **"How We Do It: Application of State-of-the-Art MF and PV Care Today...With an Eye Toward How New Evidence and Combinations Will Be Leveraged Tomorrow."**

This live, hybrid educational symposium brings together a panel of experts on the management of myeloproliferative neoplasms (MPNs) to discuss the current best practices and ongoing clinical trials focusing on the management of myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). The program will include presentations drilling down on special populations of patients with these diseases and new agents being developed, followed by discussion of challenging cases to illustrate these concepts in the context of clinical practice.

In working together with PER®, we strive to make this activity, along with all of PER®'s accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with MPNs.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the management of MPNs. Let's work together to make this an educational experience that will make a positive difference for our patients.

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Andrew Kuykendall, MD

Assistant Member
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL

Jim Palatine, RPh, MBA

President
Physicians' Education Resource®, LLC
Pharmacy Times® Continuing Education
Cranbury, NJ
jpalatine@mjhlifesciences.com

Agenda

11:00 AM	Welcome and Program Overview	Andrew Kuykendall, MD
11:05 AM	Assessing Diagnosis of MPNs in 2022 and Existing Unmet Needs	Lucia Masarova, MD
11:25 AM	Where We Are (and Where We're Going)	Andrew Kuykendall, MD
11:40 AM	Patient Case #1: Patient With Intermediate-Risk MF	Marina Kremyanskaya, MD, PhD
12:10 PM	Patient Case #2: Patient With High-Risk MF	Douglas Tremblay, MD
12:25 PM	Leveraging Evolving Evidence for State-of-the-Art Polycythemia Vera	Marina Kremyanskaya, MD, PhD
12:40 PM	Patient Case #3: Patient With High-Risk PV	Lucia Masarova, MD
12:55 PM	Patient Case #4: Patient With High-Risk ET	Douglas Tremblay, MD
1:10 PM	Question & Answer Session	Andrew Kuykendall, MD
1:20 PM	Postassessment Questions	Andrew Kuykendall, MD
1:25 PM	Preview of MPN Data preceding the 2022 ASH Annual Meeting	Andrew Kuykendall, MD
1:30 PM	Adjourn	Andrew Kuykendall, MD

Upcoming PER® Conferences

2022

Inaugural International Congress Pediatric Oncology

December 16

2023

<i>The 1st Annual Hawaii Cancer Conference: Cases and Conversation in Lung Cancer</i>	Honolulu, HI	January 21
<i>20th Annual Winter Lung Conference®</i>	Hollywood, FL	February 3-5
<i>19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®</i>	Dallas, TX	February 4
<i>27th Annual International Congress on Hematologic Malignancies®</i>	Miami Beach, FL	February 23-26
<i>40th Annual Miami Breast Cancer Conference®</i>	Miami Beach, FL	March 2-5
<i>New York NYGU™ 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies</i>	New York, NY	March 10-11
<i>8th Annual School of Gastrointestinal Oncology®</i>	Orlando, FL	May 6
<i>14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies</i>		May 13
<i>7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards</i>	New York, NY	June, 24
<i>22nd Annual International Congress on the Future of Breast Cancer® East</i>	New York, NY	July 15-16
<i>24th Annual International Lung Cancer Congress®</i>	Huntington Beach, CA	July 27-29
<i>22nd Annual International Congress on the Future of Breast Cancer® West</i>	San Diego, CA	July 28-29
<i>20th Annual Meeting of the International Society of Gastrointestinal Oncology® -</i>	Tempe, AZ	October 13-14
<i>41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®</i>	New York, NY	November 8-10
<i>17th Annual New York Lung Cancers Symposium®</i>	New York, NY	November 11

Virtual Conference

In-Person + Virtual Conference

Target Audience

This educational activity is directed toward medical oncologists, hematologic oncologists, hematologists, pharmacists, NP/PAs, nurses, and other health care professionals involved in the treatment of patients with MPNs.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Determine factors that inform personalized treatment decisions in patients with MF, PV, and ET based on genetics, risk stratification, and symptom burden;
- Outline the mechanistic rationale for the application of current and emerging therapeutic approaches for the management of MPNs;
- Assess the efficacy and safety profiles of current and emerging therapeutic strategies in MPNs across lines of therapy; and
- Integrate recent clinical trial evidence and guidelines to individualize decisions among patients with MPNs, including management of treatment-related toxicities.

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER[®] website by 12 PM EDT on Monday, December 12, 2022.

To access these materials, please visit <https://www.gotoper.com/mpn1222iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<https://www.gotoper.com/mpn1222iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain accessible until January 23, 2023.

Accreditation/Designation of Credit

Physicians' Education Resource[®], LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource[®], LLC designates this live activity for a maximum of 2.5 *AMA PRA Category 1 Credits™*.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource[®], LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.5 Contact Hours.

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Constellation Pharmaceuticals, a MorphoSys company; Geron Corporation; Imago BioSciences; Incyte Corporation; Kartos Therapeutics; PharmaEssentia USA Corporation; Protagonist Therapeutics; and Sumitomo Pharma Oncology.

Thank you for attending **How We Do It: Application of State-of-the-Art MF and PV Care Today....**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER[®] accredited CE activities.



Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: Lucia Masarova, MD, and the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau
Marina Kremyanskaya, MD, PhD	Bristol Myers Squibb, Constellation, Incyte, Kronos, Kura, Protagonist	AbbVie, CTI, Incyte, MorphoSys/Constellation, Protagonist	AbbVie, Celgene
Andrew Kuykendall, MD	Blueprint, Bristol Myers Squibb, MorphoSys, Prelude, Protagonist, Sierra Oncology	AbbVie, Biopharma, Blueprint, Bristol Myers Squibb, CTI, GSK, Imago, Incyte, MorphoSys, Novartis, Protagonist	Blueprint
Douglas Tremblay, MD	Astellas, Gilead	AbbVie, GSK	

**Information accurate at time of posting*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair



Andrew Kuykendall, MD

Assistant Member
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL

Faculty



Marina Kremyanskaya MD, PhD

Associate Professor
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY



Lucia Masarova, MD

Assistant Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX



Douglas A. Tremblay, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY


Notes

Did you miss one of our sessions?


Check out the On-Demand Video Updates
from the Annual Hematology Meeting

—*Rapid Archive from*→ **NEW ORLEANS**


Archive will be available 24 hours after the live program ends.



**Optimized use of MRD in
Hematologic Malignancies**




State-of-the-Art CMV Care




**Emerging Treatments for
Anemia in CKD**



**Holistic Approaches in
Sickle Cell Disease Treatment**




**Diagnosis and Treatment of
Hemolytic Anemias**




**Optimized Treatments for
ALL in Adolescents and Adults**




**Multidisciplinary Management
of BPDCN**




**Maximizing Clinical Practice
for Hodgkin Lymphoma**



**State-of-the-Art Care for
MF and PV**




**Exploring Gene Therapy in
Hemophilia B**



**Diagnosing Uncommon
Hematologic Disorders**



**Novel Therapies to Prevent
and Treat GvHD**



**Novel Treatments for Indolent
and Aggressive B-Cell Lymphomas**



**Treating Transfusion-Related
Iron Overload**



Scan the QR code below
or visit gotoper.com/ash22
to view the symposia archive.

 **PER**[®]
Physicians'
Education
Resource, LLC
gotoper.com